The New England Journal of Medicine, the world's most influential and widely read medical periodical, features a study this week about a Phase 2 clinical trial of VX-770, an oral drug in development that targets the root cause of cystic fibrosis.
Site Search
Showing 61 - 70 of 615 results
News
|
|
3 min read
This year, Cystic Fibrosis Advocates inspired new champions in Washington, D.C. and in state capitols across the country to take action on critical CF-related issues.
News
|
|
2 min read
News
|
|
2 min read
Chad Riedy and Jaclyn and Drew Strube will help lead the Cystic Fibrosis Foundation's advocacy work to inspire action and help shape public policies that help people with CF access high-quality, specialized care.
News
|
|
3 min read
News
|
|
1 min read
News
|
|
1 min read
News
|
|
1 min read